Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1617-1631
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1617
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1617
Table 3 Cupic study evaluation of the risk/benefit of the treatment cirrhotic patients with telaprevir or boceprevir triple therapy considering the chances of death or severe complications and sustained virologic response 12 according to cutoffs of serum albumin level and platelet count n (%)
Factors | Platelet count | Platelet count |
> 100000/mm3 | ≤100000/mm3 | |
Serum albumin level > 35 g/L | ||
Patients with severe complications or death) | 19 (6.2) | 9 (12.2) |
SVR12 | 168 (54.9) | 27 (36.5) |
Serum albumin level > 35 g/L | ||
Patients with severe complications or death | 5 (16.1) | 19 (51.4) |
SVR12 | 9 (29.0) | 10 (27.0) |
- Citation: Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7(12): 1617-1631
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1617.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1617